Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (13804)	12/12/2005 1:38:20 PM
From: Galirayo	Respond to of 23958

That's like Blood Stuff right ?? <g> Message 21964636

To: Jibacoa who wrote (13804)	12/12/2005 1:47:17 PM
From: Galirayo	Read Replies (1) \| Respond to of 23958

Should we be watching MLNM too ?? finance.yahoo.com PRINCETON, N.J., Dec. 12 /PRNewswire-FirstCall/ -- Cytogen Corporation (Nasdaq: CYTO - News) announced today the presentation of preclinical data on its flagship product QUADRAMET® (samarium Sm-153 lexidronam) in combination with bortezomib (Velcade®, Millennium Pharmaceuticals, Inc.). Kosan Biosciences Says Drug Trial Results Positive; Shares Fall 20 Percent in Midday Trading ATLANTA (AP) -- Kosan Biosciences Inc. said Monday that its experimental drug showed signs of anticancer activity in two early trials, yet the biotech firm's shares fell 20 percent in midday trading. The drug developer said its KOS-953 drug demonstrated encouraging activity in two Phase I studies of patients with a blood cancer called multiple myeloma. One study tested KOS-953 alone, while another looked at it in conjunction with the Velcade drug made by Millennium Pharmaceuticals Inc.